HDACi and bone in Multiple myeloma

点击翻译按钮获取中文摘要

Multiple myeloma (MM) is an incurable hematological malignancy with 1,400 people diagnosed each year. Severe bone loss occurs in up to 90% of these patientssignificantly impacting on quality of life resulting in severe bone pain and bone lesions that fail to heal. This project proposes that a novel histone deacetylase inhibitor could provide an appropriate therapeutic strategy that inhibits tumor growth and prevents bone loss whilst also promoting bone repair.